None listed
Conditions
Brief summary
The primary purpose of the study is to verify if patients with metastatic colorectal cancer, who have been treated with first-line triple drug combination FOLFOXIRI and who have underwnt to radical surgical resection of metastases, may reach a prolonged overall survival and so a chance of cure for their metastatic diseases
Interventions
Observation: metastatic colorectal cancer patients who have been treated in first-line with FOLFOXIRI (a triple drug combination of irinotecan 165 mg/square meter ("sqm") endovenous ("ev") in 1 hour, oxaliplatin 85 mg/sqm ev in 2 hours and 5-fluorouracil 3200 mg/sqm as a 48-hour continous infusion ev plus leucovorin 200 mg/sqm ev in 2 hours, every 14 days for 12 cycles) and who underwent radical surgical resection of metastases will be followed up yearly for 5 years after the diagnosis of diseas
Observation: metastatic colorectal cancer patients who have been treated in first-line with FOLFOXIRI (a triple drug combination of irinotecan 165 mg/square meter ("sqm") endovenous ("ev") in 1 hour, oxaliplatin 85 mg/sqm ev in 2 hours and 5-fluorouracil 3200 mg/sqm as a 48-hour continous infusion ev plus leucovorin 200 mg/sqm ev in 2 hours, every 14 days for 12 cycles) and who underwent radical surgical resection of metastases will be followed up yearly for 5 years after the diagnosis of disease to collect their survival status.
Sponsors
Gruppo Oncologico del Nord-Ovest "GONO"
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
Metastatic colorectal cancer; Unresectable disease at diagnosis; First-line treatment with FOLFOXIRI
Exclusion criteria
Treatment with chemotherapy different from FOLFOXIRI; Eastern Cooperative Oncology Group (ECOG) Performance status (PS) >2
Outcome results
None listed